United States

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

12:20am EST
Change (% chg)

Rs5.15 (+0.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for SUN.NS


Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)


Beta: 0.26
Market Cap(Mil.): Rs1,539,252.00
Shares Outstanding(Mil.): 2,399.27
Dividend: 1.00
Yield (%): 0.16


  SUN.NS Industry Sector
P/E (TTM): 20.93 29.51 30.38
EPS (TTM): 30.66 -- --
ROI: 23.32 15.44 14.86
ROE: 22.83 16.62 16.28

U.S. states sue Mylan, Teva, others for fixing drug prices

WASHINGTON Two years after high generic drug prices became a public controversy, legal cases are starting to land.

Dec 15 2016

FDA finds quality control problems at Sun Pharma's Halol plant

MUMBAI The U.S. Food and Drug Administration (FDA) has again raised concerns about the quality control process at Indian drugmaker Sun Pharmceutical Industries' Halol factory, an inspection report obtained by Reuters shows.

Dec 13 2016

India's Sun Pharma says U.S. finds more concerns at Halol plant

MUMBAI Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Wednesday the U.S. health regulator has informed the company of more concerns found at its Halol manufacturing plant after a recent inspection.

Dec 07 2016

BRIEF-Sun Pharma Industries launches first branded ophthalmic product Bromsite in USA

* Announcement of launches first branded ophthalmic product Bromsite in USA

Nov 28 2016

BRIEF-Sun Pharma enters into deal to buy 85.1 pct of Russia's JSC Biosintez

* Says company has entered into an agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company

Nov 22 2016

UPDATE 2-Sun Pharma expects U.S. drug pricing pressures to continue

* Says expects pricing pressure in U.S. to continue (Adds comments from conference call)

Nov 10 2016

BRIEF-India's Sun Pharma says unsure if Halol plant will be cleared in next 5 months

* India's Sun Pharma said it was unsure if Halol plant would be cleared in the next five months, as the FDA may take time Further company coverage: (Reporting By Zeba Siddiqui)

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries exec says pricing pressure in the U.S. will continue

* Sun Pharmaceutical Industries exec says awaiting US FDA reinspection of Halol plant

Nov 10 2016

India's Sun Pharma Q2 profit beats estimates

MUMBAI, Nov 10 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported on Thursday a quarterly profit that more than doubled from last year, outpacing analysts' expectations.

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries approves amalgamation of 4 units into co

* Says approves scheme of amalgamation of Sun Pharma Medisales, Ranbaxy Drugs Ltd, Gufic Pharma, Vidyut Investments into co Source text: http://bit.ly/2g0Jbpb Further company coverage:

Nov 10 2016

Earnings vs. Estimates